Key result
Postdilation after PCI in ACS tends to reduce major cardiovascular events but increases all-cause death ~49%.
Why the study?
The effect of postdilation after percutaneous coronary intervention in patients with acute coronary syndrome remains controversial.
Does postdilation after percutaneous coronary intervention reduce major adverse cardiovascular events in patients with acute coronary syndrome?
Meta-Analysis
Does postdilation after percutaneous coronary intervention reduce major adverse cardiovascular events in patients with acute coronary syndrome?
In patients with acute coronary syndrome undergoing percutaneous coronary intervention, postdilation may tend to reduce MACE but is associated with a significant increase in all-cause death.
Answers are grounded in this paper and cite their sources.
Postdilation after PCI in ACS warrants caution due to higher all-cause death; leaves open net benefit on MACE pending randomized trials.
Objective. The effect of postdilation in patients with acute coronary syndrome is still controversial. This meta-analysis aims to analyze the clinical and angiographic outcomes of postdilation after percutaneous coronary intervention in patients with acute coronary syndrome. Methods. PubMed, Embase, the Cochrane Library, Web of Science, CNKI, and Wangfang databases were searched from inception to August 30, 2020. Eligible studies from acute coronary syndrome patients treated with postdilation were included. The primary clinical outcome was major adverse cardiovascular events (MACE), the secondary clinical outcomes comprised all-cause death, stent thrombosis, myocardial infarction, and target vessel revascularization, and the angiographic outcomes were no reflow and slow reflow. Results. 11 studies met inclusion criteria. In clinical outcomes, our pooled analysis demonstrated that the postdilation had a tendency of decreasing MACE (OR = 0.67, 95% CI 0.45–1.00; <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>P</a:mi> </a:math> = 0.05) but significantly increased all-cause death (OR = 1.49, 95% CI 1.05–2.12; <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>P</c:mi> </c:math> = 0.03). No significant difference existed in stent thrombosis (OR = 0.71, 95% CI 0.40–1.26; <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>P</e:mi> </e:math> = 0.24), myocardial infarction (OR = 1.40, 95% CI 0.51–3.83; <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>P</g:mi> </g:math> = 0.51), and target vessel revascularization (OR = 0.61, 95% CI 0.21–1.80; <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mi>P</i:mi> </i:math> = 0.37) between postdilation and non-postdilation groups. In angiographic outcomes, there were no significant differences in no reflow (OR = 1.19, 95% CI 0.54–2.65; <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mi>P</k:mi> </k:math> = 0.66) and slow reflow (OR = 1.12, 95% CI 0.93–1.35; <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"> <m:mi>P</m:mi> </m:math> = 0.24) between two groups. Conclusions. The postdilation tends to reduce the risk of MACE but significantly increases all-cause death, without significantly affecting stent thrombosis, myocardial infarction, target vessel revascularization, and coronary TIMI flow grade. However, more randomized controlled trials are required for investigating the effect of postdilation for patients with acute coronary syndrome (registered by PROSPERO, CRD42020160748).
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a meta-analysis in Acute coronary syndrome. Postdilation vs. Non-postdilation was evaluated on Major adverse cardiovascular events (MACE) (OR 0.67, 95% CI 0.45-1.00, p=0.05). Postdilation after percutaneous coronary intervention in acute coronary syndrome tended to decrease major cardiovascular events but increased all-cause death.
Synapse has enriched 10 related papers. Consider them for comparative context: